GlassScriptPhysician profile
Trent P Pierce
NPI 1083626998
$375.81
in general payments reported to CMS, 2019-2025
13 companies · $45.61 in 2025
The $45.61 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.85 · 2024: $235 · 2025: $45.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $107.00 | 2024 | |
| Theratechnologies INC. | $52.34 | 2023-2024 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $32.80 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $31.38 | 2024 | |
| Merck Sharp & Dohme LLC | $30.55 | 2024-2025 | Delstrigo, Pifeltro, Capvaxive |
| Abiomed | $20.03 | 2024 | Impella |
| Lilly USA, LLC | $15.86 | 2025 | Jardiance |
| Cequr Corporation | $15.00 | 2025 | Cequr Simplicity |
| Qiagen, LLC | $14.94 | 2023 | |
| Neurocrine Biosciences, INC. | $14.70 | 2023 | Ingrezza |
| Edwards Lifesciences Corporation | $14.41 | 2024 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $14.05 | 2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.75 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trent Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.